Vertical Heterophoria Treatment Ameliorates Headache, Dizziness and Anxiety.
Background: Vertical heterophoria is known to cause headache, dizziness, and anxiety, three commonly comorbid diseases. Earlier studies have shown that correction of vertical heterophoria smaller than the standard error of existing phoria tests can reduce symptoms. This study is designed to demonstr...
| Publicado en: | Optometry & Visual Performance Vol. 8; no. 1; pp. 24 - 35 |
|---|---|
| Autores principales: | , |
| Formato: | research tables/charts Journal Article |
| Publicado: |
Optometric Extension Program
2020
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=142549021&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 142549021 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 23253479 HOOW jtl: Optometry & Visual Performance issn: 23253479 maglogo: N pubinfo: dt: 2020 vid: 8 iid: 1 pid: 46881 pub: Optometric Extension Program place: Lutherville Timonium, Maryland artinfo: ui: 142549021 142549021 142549021 142549021 ppf: 24 ppct: 11 formats: tig: atl: Vertical Heterophoria Treatment Ameliorates Headache, Dizziness and Anxiety. aug: au: Feinberg, Debby L. Rosner, Mark S. affil: Director of Clinical Care and Education, NeuroVisual Medicine Institute Illinois College of Optometry, 1983 University of Michigan, BS, 1979 sug: subj: Strabismus Therapy Headache Prevention and Control Dizziness Prevention and Control Anxiety Prevention and Control Eyeglasses Outcomes (Health Care) Human Retrospective Design Optometry United States Scales Visual Acuity Coefficient alpha Male Female Child Adolescence Adult Middle Age Aged Child: 6-12 years Adolescent: 13-18 years Adult: 19-44 years Middle Aged: 45-64 years Aged: 65+ years Male Female ab: Background: Vertical heterophoria is known to cause headache, dizziness, and anxiety, three commonly comorbid diseases. Earlier studies have shown that correction of vertical heterophoria smaller than the standard error of existing phoria tests can reduce symptoms. This study is designed to demonstrate the effectiveness of prism lenses correcting for small amounts of vertical heterophoria in reducing symptoms in patients presenting with headache, vestibular and/or anxiety symptoms, and also to demonstrate effectiveness of micro-prism lenses to diagnose vertical heterophoria. Methods: Retrospective study of patients diagnosed with vertical heterophoria who responded to treatment with micro-prism lenses and completed survey instruments at an optometry clinic in Michigan, USA. This study included 111 patients presenting with vertical heterophoria symptoms between 07/2009 and 06/2011 who self-reported significant disability from headache, dizziness, and/or anxiety on the Headache Disability Inventory, Dizziness Handicap Inventory, and Zung Self-Rating Anxiety Scale respectively, and completed pre- and posttreatment survey instruments. Participants were treated by application of corrective micro-prism lenses (vertical prism 0.25D-2.50D) followed by 1-3 lens prescription adjustments over 8-12 weeks. Outcomes were measured by repeating survey instruments. Results: Mean HDI score reduced from 37.55 to 22.13, effect size d = .54. Mean DHI score reduced from 38.01 to 18.68, effect size d = .72. Mean SAS score reduced from 42.13 to 34.22, effect size d = .80. No side effects reported. Conclusions: Screening and treatment for vertical heterophoria using micro-prism lenses provided significant symptom relief for patients with headache, dizziness, and anxiety symptoms that had not responded to traditional treatments. pubtype: Academic Journal doctype: research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|